购物车
- 全部删除
- 您的购物车当前为空
Motesanib (AMG 706) 是有效的、ATP 竞争性的 VEGFR1/2/3 的抑制剂,其IC50值为 2 nM/3 nM/6 nM,与对 Kit 的选择性相似,是 PDGFR 和 Ret 的 10 倍多。
Motesanib (AMG 706) 是有效的、ATP 竞争性的 VEGFR1/2/3 的抑制剂,其IC50值为 2 nM/3 nM/6 nM,与对 Kit 的选择性相似,是 PDGFR 和 Ret 的 10 倍多。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 198 | 现货 | |
5 mg | ¥ 446 | 现货 | |
10 mg | ¥ 538 | 现货 | |
25 mg | ¥ 863 | 现货 | |
50 mg | ¥ 1,230 | 现货 | |
100 mg | ¥ 1,730 | 现货 | |
500 mg | ¥ 4,260 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 496 | 现货 |
产品描述 | Motesanib (AMG 706) is an orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), Kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation. |
靶点活性 | VEGFR1:2 nM, c-Kit:8 nM, VEGFR2:3 nM, VEGFR3:6 nM |
体外活性 | Motesanib对人VEGFR家族具有广泛活性,对EGFR、Src和p38激酶的选择性>1000倍。Motesanib显著抑制VEGF诱导的HUVECs细胞增殖,IC50为10 nM,而对bFGF诱导的细胞增殖影响较小,IC50 > 3000 nM。此外,Motesanib强效抑制PDGF诱导的细胞增殖和SCF诱导的c-kit磷酸化,IC50分别为207 nM和37 nM,但对EGF诱导的EGFR磷酸化和A431细胞的细胞活力无效[1]。尽管对HUVECs细胞生长的抗增殖活性较小,Motesanib处理显著增强了细胞对分段放射线的敏感性[2]。 |
体内活性 | Motesanib (100 mg/kg) 显著抑制了 VEGF 引起的血管通透性,呈时间依赖性。通过口服 Motesanib 每天两次或一次的方式,以剂量依赖性强效抑制 VEGF 引发的血管生成,使用大鼠角膜模型,ED50 分别为 2.1 mg/kg 和 4.9 mg/kg。Motesanib 引起剂量依赖的 A431 异种移植瘤退缩,通过选择性针对肿瘤细胞中的新生血管化。Motesanib 结合放射治疗在头颈部鳞状细胞癌 (HNSCC) 异种移植模型中显示出显著的抗肿瘤活性[2]。此外,Motesanib 治疗在 MCF-7, MDA-MB-231 或 Cal-51 异种移植瘤中引起显著的剂量依赖性肿瘤生长和血管密度减少,与多西他赛或他莫昔芬联合时效果可显著增强[3]。 |
激酶实验 | Optimal enzyme, ATP, and substrate (gastrin peptide) concentrations are established for each enzyme using homogeneous time-resolved fluorescence (HTRF) assays. Motesanib is tested in a 10-point dose-response curve for each enzyme using an ATP concentration of two-thirds Km?for each. Most assays consist of enzyme mixed with kinase reaction buffer [20 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 5 mM MnCl2, 100 mM NaCl, 1.5 mM EGTA]. A final concentration of 1 mM DTT, 0.2 mM NaVO4, and 20 μg/mL BSA is added before each assay. For all assays, 5.75 mg/mL streptavidin-allophycocyanin and 0.1125 nM Eu-PT66 are added immediately before the HTRF reaction. Plates are incubated for 30 minutes at room temperature and read on a Discovery instrument. IC50 values are calculated using the Levenberg-Marquardt algorithm into a four-parameter logistic equation. |
细胞实验 | Cells are preincubated for 2 hours with different concentrations of Motesanib, and exposed with 50 ng/mL VEGF or 20 ng/mL bFGF for an additional 72 hours. Cells are washed twice with DPBS, and plates are frozen at -70°C for 24 hours. Proliferation is assessed by the addition of CyQuant dye, and plates are read on a Victor 1420 workstation. IC50 data are calculated using the Levenberg-Marquardt algorithm into a four-parameter logistic equatio. |
别名 | 莫替沙尼, 莫特塞尼, AMG 706 |
分子量 | 373.45 |
分子式 | C22H23N5O |
CAS No. | 453562-69-1 |
Smiles | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 |
密度 | 1.251 g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (133.88 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容